The PD-L1 inhibitor atezolizumab was recently shown to be effective in children and adults with advanced alveolar soft part sarcoma (ASPS) with a response rate of 37% and is now FDA approved for this indication [204]. This evidence concerns the gene CD274 and alveolar soft part sarcoma.